Woolsey Pharmaceuticals
Private Company
Funding information not available
Overview
Woolsey Pharmaceuticals is a private, pre-revenue biotech company targeting high-need neurodegenerative diseases, with ALS as its lead indication. The company's most advanced asset is BRAVYL (oral fasudil), a Rho kinase inhibitor, which has completed a Phase 2a study in ALS patients, showing promising biomarker data. While initially described as operating in oncology and rare disease, the website content reveals a sharp, current focus on neurodegenerative disorders, positioning the company in a challenging but critically important therapeutic area with significant unmet medical need.
Technology Platform
Small molecule Rho kinase (ROCK) inhibition platform, leveraging repurposed compound fasudil.
Opportunities
Risk Factors
Competitive Landscape
The ALS treatment landscape is active but still has limited effective options (riluzole, edaravone, tofersen for SOD1-ALS). Woolsey competes with other companies developing disease-modifying therapies across various mechanisms. Its competitive edge lies in BRAVYL's repurposed safety profile and the promising Phase 2a biomarker signal suggesting neuroprotection.